These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 29236425)

  • 21. Effect of treatment with depot somatostatin analogue octreotide on primary hyperparathyroidism (PHP) in multiple endocrine neoplasia type 1 (MEN1) patients.
    Faggiano A; Tavares LB; Tauchmanova L; Milone F; Mansueto G; Ramundo V; De Caro ML; Lombardi G; De Rosa G; Colao A
    Clin Endocrinol (Oxf); 2008 Nov; 69(5):756-62. PubMed ID: 18485119
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of octreotide long-acting repeatable in neuroendocrine tumors: RADIANT-2 placebo arm post hoc analysis.
    Strosberg JR; Yao JC; Bajetta E; Aout M; Bakker B; Hainsworth JD; Ruszniewski PB; Van Cutsem E; Öberg K; Pavel ME
    Endocr Relat Cancer; 2015 Dec; 22(6):933-40. PubMed ID: 26373569
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Novel pharmacologic therapies in acromegaly].
    Góth M; Hubina E; Kovács L; Szabolcs I
    Orv Hetil; 2002 May; 143(19 Suppl):1057-62. PubMed ID: 12063860
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly.
    Colao A; Ferone D; Marzullo P; Cappabianca P; Cirillo S; Boerlin V; Lancranjan I; Lombardi G
    J Clin Endocrinol Metab; 2001 Jun; 86(6):2779-86. PubMed ID: 11397887
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High-dose octreotide acetate for management of gastroenteropancreatic neuroendocrine tumors.
    Chadha MK; Lombardo J; Mashtare T; Wilding GE; Litwin A; Raczyk C; Gibbs JF; Kuvshinoff B; Javle MM; Iyer RV
    Anticancer Res; 2009 Oct; 29(10):4127-30. PubMed ID: 19846960
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-acting somatostatin analog therapy of acromegaly: a meta-analysis.
    Freda PU; Katznelson L; van der Lely AJ; Reyes CM; Zhao S; Rabinowitz D
    J Clin Endocrinol Metab; 2005 Aug; 90(8):4465-73. PubMed ID: 15886238
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical value of monitoring plasma octreotide levels during chronic octreotide long-acting repeatable therapy in carcinoid patients.
    Woltering EA; Salvo VA; O'Dorisio TM; Lyons J; Li G; Zhou Y; Seward JR; Go VL; Vinik AI; Mamikunian P; Mamikunian G
    Pancreas; 2008 Jul; 37(1):94-100. PubMed ID: 18580450
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Depot long-acting somatostatin analog (Sandostatin-LAR) is an effective treatment for acromegaly.
    Stewart PM; Kane KF; Stewart SE; Lancranjan I; Sheppard MC
    J Clin Endocrinol Metab; 1995 Nov; 80(11):3267-72. PubMed ID: 7593436
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Octreotide long-acting repeatable among elderly patients with neuroendocrine tumors: a survival analysis of SEER-Medicare data.
    Shen C; Shih YC; Xu Y; Yao JC
    Cancer Epidemiol Biomarkers Prev; 2015 Nov; 24(11):1656-65. PubMed ID: 26315553
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Optimizing medical therapy of acromegaly: beneficial effects of cabergoline in patients uncontrolled with long-acting release octreotide.
    Jallad RS; Bronstein MD
    Neuroendocrinology; 2009; 90(1):82-92. PubMed ID: 19439914
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A cautionary note on generic depot octreotide.
    Gallardo W; de Las Casas MI; Mercado M
    Pituitary; 2015 Aug; 18(4):581-2. PubMed ID: 25064084
    [No Abstract]   [Full Text] [Related]  

  • 32. Patient and Healthcare Provider Perspectives of First-Generation Somatostatin Analogs in the Management of Neuroendocrine Tumors and Acromegaly: A Systematic Literature Review.
    Cella D; Evans J; Feuilly M; Neggers S; Van Genechten D; Herman J; Khan MS
    Adv Ther; 2021 Feb; 38(2):969-993. PubMed ID: 33432541
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of preoperative use of long-acting octreotide on growth hormone secreting pituitary adenoma and transsphenoidal surgery.
    Yin J; Su CB; Xu ZQ; Yang Y; Ma WB; Tao W; Yang Z; Xia XW
    Chin Med Sci J; 2005 Mar; 20(1):23-6. PubMed ID: 15844307
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Estimation of efficacy of the octreotide LAR administration in the patients with somatotropinoma].
    Waśko R; Bolko P; Kostrzewski J; Horst-Sikorska W; Liebert W; Sowiński J
    Pol Arch Med Wewn; 2001 Aug; 106(2):693-8. PubMed ID: 11926144
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Octreotide lar affects the volume of pituitary adenoma in acromegalic patients.
    Bałdys-Waligórska A; Krzentowska-Korek A; Gołkowski F; Sokołowski G; Hubalewska-Dydejczyk A
    Exp Clin Endocrinol Diabetes; 2011 May; 119(5):295-9. PubMed ID: 21264808
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly.
    Mercado M; Borges F; Bouterfa H; Chang TC; Chervin A; Farrall AJ; Patocs A; Petersenn S; Podoba J; Safari M; Wardlaw J;
    Clin Endocrinol (Oxf); 2007 Jun; 66(6):859-68. PubMed ID: 17465997
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Somatostatin analog octreotide LAR in gastro-entero-pancreatic tumors.
    Oberg K
    Expert Rev Anticancer Ther; 2009 May; 9(5):557-66. PubMed ID: 19445573
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Octreotide long-acting repeatable for acromegaly.
    Cozzi R; Attanasio R
    Expert Rev Clin Pharmacol; 2012 Mar; 5(2):125-43. PubMed ID: 22390555
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy of a slow-release formulation of lanreotide (Autogel) 120 mg) in patients with acromegaly previously treated with octreotide long acting release (LAR): an open, multicentre longitudinal study.
    Ronchi CL; Boschetti M; Degli Uberti EC; Mariotti S; Grottoli S; Loli P; Lombardi G; Tamburrano G; Arvigo M; Angeletti G; Boscani PF; Beck-Peccoz P; Arosio M;
    Clin Endocrinol (Oxf); 2007 Oct; 67(4):512-9. PubMed ID: 17555511
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-acting formulations of somatostatin analogues.
    Anthony LB
    Ital J Gastroenterol Hepatol; 1999 Oct; 31 Suppl 2():S216-8. PubMed ID: 10604134
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.